Authors
Latest:
Can Global Innovation in Oncology be Sustained in the Face of Price Controls?Pricing in the context of patient access and affordability continues to present problems and constitute a real threat to innovation. Meaningful reform involves rectifying market imperfections in public and private third-party prescription drug payment sectors, writes Robert A. Freeman.
Latest:
Digital Transformation: A Guide for Pharma MarketersOrganizations need to be correctly set up to deploy AI and machine learning. A new approach to processes and content is often required, write Jan van den Burg and Abid Rahman.
Latest:
Four Critical Considerations for Launching Digital Diagnostic ToolsCreating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Latest:
How Machine Learning Gives Life Sciences Sales a Competitive AdvantageHow machine learning can provide an on-demand portfolio-wide view of optimal provider targeting and related field deployment.
Latest:
PDPRA's Operational ChallengesWhether or not the new Prescription Drug Pricing Reduction Act is a good policy, if it is enacted, its proposals have to work as intended and ensure compliant operationalization, writes Jeremy Docken.
Latest:
Text ROI to 55150Channel mix nirvana. It’s like a group of superheroes with all different strengths; working together to achieve the extraordinary. Deploy different channels to achieve different objectives.
Latest:
Evaluating Electronic Benefit Verification Solutions for Your Patient Support ProgramAs specialty therapies evolve and more treatment options for chronic and complex diseases become available, patients are seeking treatment options that are both effective and affordable.
Latest:
505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic CompaniesAs the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Latest:
Commercial Models for the Changing Life Sciences MarketLife sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
Latest:
505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic CompaniesAs the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Latest:
505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic CompaniesAs the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Latest:
Beyond “Tech Talent”: New Leadership in Pharma’s Digital AgeWith an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?
Latest:
Beyond “Tech Talent”: New Leadership in Pharma’s Digital AgeWith an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?
Latest:
435 New Medicines in Development for “Older Americans”According to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA), America’s biopharmaceutical research companies are developing 435 new medicines to target 15 leading chronic conditions affecting the Medicare population.
Latest:
Turning Commercial Compliance Roadblocks into a Springboard for InnovationWhile new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
Latest:
Turning Commercial Compliance Roadblocks into a Springboard for InnovationWhile new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
Latest:
The Bad Rap on Pharma: In Defense of PatentsA look at drug pricing and patents and the role for patents and how they are under attack.
Latest:
Turning Commercial Compliance Roadblocks into a Springboard for InnovationWhile new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
Latest:
Cure for the Common Cold Chain BreakIn medicines, as in life, the journey is just as important as the end result
Latest:
How to Communicate About an Ongoing Epidemic of Historic ProportionsThe industry faces a problem of medical education and communication in regards to vaccinations.
Latest:
How to Communicate About an Ongoing Epidemic of Historic ProportionsThe industry faces a problem of medical education and communication in regards to vaccinations.
Latest:
How Rare Disease Marketing Will Stretch Beyond the PatientThe foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.
Latest:
How Rare Disease Marketing Will Stretch Beyond the PatientThe foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.
Latest:
California Law Requires Legal, Compliance Scrutiny to Maintain Pharma Data SharingA summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.
Latest:
How Cell and Gene Therapy Companies Can Adapt in an Evolving Commercial LandscapeThree changes manufacturers should consider in the wake of COVID-19.
